SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma
SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.
Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in January of 2016. This is the final update, as this study is complete.
Inclusion Criteria:
Exclusion Criteria:
Wheeling, Ohio 26003, United States
Falls Church, Vermont 22044, United States
Derqui, Pilar, Buenos Aires B1629AHJ, Argentina
Rosklide, DK-4000, Denmark
Bad Woerrishofen, Bavaria 86825, Germany
Gars Am Inn, Bavaria 83536, Germany
Lahnau, Hesse 35633, Germany
Kleve-Materborn, North Rhine-Westphalia 47533, Germany
San Borja, Lima, L36, Peru
Dasmariñas, Cavite, 4114, Philippines
Cape Town, Gauteng 7505, South Africa
Eloffsdal, Gauteng 0084, South Africa
Die Wilgers, 0184, South Africa
Basurto/Bilbao, 48013, Spain
Canet de Mar - Barcelona, 08360, Spain
Illescas-Toledo, 45004, Spain
Pozuelo de Alarcón/Madrid, 28223, Spain
Sagunto/Valencia, 46520, Spain
Koahsiung, 81346, Taiwan
Putzu, 613, Taiwan
Merseyside, CH41 0DD, United Kingdom